Literature DB >> 11908677

Hepatocyte growth factor expression in human cancer and therapy with specific inhibitors.

R Haddad1, K E Lipson, C P Webb.   

Abstract

Hepatocyte growth factor/Scatter Factor (HGF/SF) mediated stimulation of the Met receptor tyrosine kinase results in pleiotropic cellular effects including proliferation, morphogenesis, motility and invasion. In vivo, HGF/SF-Met activation has been shown to participate in tumorigenesis, angiogenesis and metastasis. Coupled with accumulating evidence that aberrant HGF/SF-Met expression is frequently observed in a variety of human tumors, often in association with progressive disease, these data present HGF/SF-Met as an attractive target for therapeutic intervention in human cancer. In this review, we will present the most compelling evidence suggesting a key role for HGF/SF-Met signaling in tumorigenesis, and discuss several possible therapeutic strategies.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11908677

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  7 in total

1.  Effects of adenoviral-mediated gene transduction of NK4 on proliferation, movement, and invasion of human colonic LS174T cancer cells in vitro.

Authors:  Jian-Zheng Jie; Jian-Wei Wang; Jian-Guo Qu; Wei Wang; Tao Hung
Journal:  World J Gastroenterol       Date:  2006-07-07       Impact factor: 5.742

2.  Endosomal dynamics of Met determine signaling output.

Authors:  Dean E Hammond; Stephanie Carter; John McCullough; Sylvie Urbé; George Vande Woude; Michael J Clague
Journal:  Mol Biol Cell       Date:  2003-04       Impact factor: 4.138

3.  A phase I trial of topotecan plus tivantinib in patients with advanced solid tumors.

Authors:  Stephen V Liu; Susan G Groshen; Karen Kelly; Karen L Reckamp; Chandra Belani; Timothy W Synold; Amir Goldkorn; Barbara J Gitlitz; Mihaela C Cristea; I-Yeh Gong; Thomas J Semrad; Yucheng Xu; Tong Xu; Marianna Koczywas; David R Gandara; Edward M Newman
Journal:  Cancer Chemother Pharmacol       Date:  2018-08-20       Impact factor: 3.333

4.  Study of critical role of c-Met and its inhibitor SU11274 in colorectal carcinoma.

Authors:  Wei Gao; Xue Bing; MingYan Li; Zhanhua Yang; Ying Li; Hua Chen
Journal:  Med Oncol       Date:  2013-03-28       Impact factor: 3.064

5.  Identification of novel cellular targets in biliary tract cancers using global gene expression technology.

Authors:  Donna E Hansel; Ayman Rahman; Manuel Hidalgo; Paul J Thuluvath; Keith D Lillemoe; Richard Schulick; Ja-Lok Ku; Jae-Gahb Park; Kohje Miyazaki; Raheela Ashfaq; Ignacio I Wistuba; Ram Varma; Lesleyann Hawthorne; Joseph Geradts; Pedram Argani; Anirban Maitra
Journal:  Am J Pathol       Date:  2003-07       Impact factor: 4.307

6.  Growth factor-induced shedding of syndecan-1 confers glypican-1 dependence on mitogenic responses of cancer cells.

Authors:  Kan Ding; Martha Lopez-Burks; José Antonio Sánchez-Duran; Murray Korc; Arthur D Lander
Journal:  J Cell Biol       Date:  2005-11-14       Impact factor: 10.539

7.  NK4 Regulates Laryngeal Squamous Cell Carcinoma Cell Properties and Inhibits Tumorigenicity by Modulating the DKK1/Wnt/β-Catenin Axis.

Authors:  Shoukai Zhang; Hulai Wei; Xiaoqin Ha; Yueyu Zhang; Yufen Guo
Journal:  Front Oncol       Date:  2021-12-14       Impact factor: 6.244

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.